Ahmed Kotb

Ahmed Kotb

Auto-generated profile, based on publicly available information

Ahmed Kotb

Department of General Surgery, Glan Clwyd Hospital, Rhyl, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
AKAhmed Kotb
Ahmed Kotb
LELouis Evans
Louis Evans
ESEmily Sams
Emily Sams
ANAndrew Naguib
Andrew Naguib
SHShahin Hajibandeh
Shahin Hajibandeh
TSThomas Satyadas
Thomas Satyadas
Shahab Hajibandeh, Ahmed Kotb, Louis Evans, Emily Sams, Andrew Naguib, Shahin Hajibandeh, Thomas Satyadas. Ann Hepatobiliary Pancreat Surg 2023;27:6-19. https://doi.org/10.14701/ahbps.22-045

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SGShirish M. Gadgeel
Shirish M. Gadgeel
ASAlice Tsang Shaw
Alice Tsang Shaw
FBFabrice Barlesi
Fabrice Barlesi
LCLucio Crinò
Lucio Crinò
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
SOSai-Hong Ignatius Ou
Sai-Hong Ignatius Ou
9063 Background: Alectinib showed robust efficacy and safety in two phase II studies (NP28673 [NCT01801111] and NP28761 [NCT01871805]) of patients (pts) with previously treated ALK+ NSCLC. A pooled analysis of these studies also showed highly consistent efficacy of alectinib in the central nervous system (CNS) (Gadgeel et al, WCLC 2015). This exploratory analysis used these pooled data to evaluate the cumulative incidence rate (CIR) of CNS and non-CNS progression for pts with and without CNS metastases (mets) at baseline (BL). Methods: All pts (n = 225) were ≥ 18 years with confirmed ALK+ NSCLC, which had progressed after prior crizotinib. They received 600 mg oral alectinib twice daily. All patients had BL imaging to detect CNS mets, with further prospective imaging as per the protocols. In this analysis, response was determined by RECIST v1.1, and progression (PD) categorized as CNS or non-CNS. CIR was calculated using competing risks methodology. Results: BL characteristics were similar in pts with (n = 136) or without (n = 89) BL CNS mets. Median follow-up was 12.8 months. CIRs at 6, 12 and 18 months are shown in the Table. In the BL CNS mets group, pts with prior radiation (RT; n = 95) had a slightly more rapid rate of CNS PD (39.7% [29.6–49.8] at 12 months) than those with no prior RT (n = 41; 20.1% [7.6–32.6] at 12 months) (p < 0.05), perhaps due to, for e.g., greater disease burden. Conclusions: These pooled phase II study data suggest that alectinib is effective in pts with BL CNS mets, regardless of prior RT. Based on the low incidence of CNS PD in pts without CNS mets at BL, alectinib may also have a potential preventative effect in these pts. The ongoing phase III ALEX study will assess rate of CNS relapse in pts receiving first-line alectinib vs crizotinib. Clinical trial information: NCT01801111 and NCT01871805.